AN
Alto Neuroscience, Inc.
ANRO · NYSE
$35.80 +0.70% (+$0.25)
1M +26.58%
Market Cap $1.26B
P/E Ratio -
Div. Yield -
ROE 46.46%
Piotroski F-Score Weak
2/9Valuation
28 /100
Expensive P/B 5.73x
P/E N/A
EV/EBITDA N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
37 /100
Average ROIC 18.43%
ROE 46.46%
ROA 33.16%
Debt
69 /100
Low Debt/Equity 0.03x
Current ratio 14.85x
Int. coverage -36.26x
Stability
44 /100
Moderate Beta 1.09x
EPS volatility 49.23%
Profitable years 0
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na ANRO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Amit Etkin
Employees
68
Headquarters
Mountain View
Nadcházející události
11 LIS
Earnings
Upcoming earnings report